Pharmaceutical Technology
MAY 18, 2023
An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. Pivotal trials on LMN-201 are expected to commence in 2023. It is compatible with standard-of-care antibiotics.
XTalks
NOVEMBER 6, 2020
Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 4, 2020
Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. OspA is one of the most dominant surface proteins expressed by the bacteria when present in the ticks that spread the disease.
pharmaphorum
DECEMBER 1, 2021
The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition.
XTalks
JULY 25, 2023
Anthrax is a rare, yet severe disease caused by the bacterium B. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. Moreover, the clinical trials demonstrated that Cyfendus exhibited a favorable tolerability profile. What Is Anthrax? Additionally, at Day 64, 86.6
XTalks
JANUARY 20, 2021
To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments).
Drug Discovery World
NOVEMBER 17, 2022
Most antibiotics are derived from genetic sequences locked within so-called biosynthetic gene clusters, which are genes that function as a unit to collectively code for a series of proteins. Cilagicin is still far from human trials. But those clusters are often inaccessible with current technologies. .
Expert insights. Personalized for you.
130 
Let's personalize your content